Tesamorelin Protocol: Complete Cycling & Dosing Guide

Overview

Tesamorelin is a synthetic GHRH (growth hormone-releasing hormone) analog designed to stimulate your body's natural GH production rather than replace it. Unlike exogenous growth hormone injection, tesamorelin preserves your natural feedback mechanisms, making it a physiologically gentler option for improving body composition, reducing visceral fat, and potentially supporting cognitive function in aging populations.

The peptide comes in lyophilized (freeze-dried) powder form and requires reconstitution before injection. It's FDA-approved for HIV-associated lipodystrophy but is widely used off-label for body composition improvement and metabolic optimization in non-HIV populations.

Key characteristics:

• Standard dose: 2 mg once daily via subcutaneous injection
• Route: Subcutaneous injection (abdomen, thigh, or arm)
• Half-life: ~26 minutes (but downstream GH effects last hours)
• Cost: $80–$400 per month depending on source and purity
• Primary effects: Visceral fat reduction (15–24%), lean mass gain (1.4 kg average), modest hepatic fat reduction

Standard Protocol

Basic Dosing Schedule

Beginner Protocol (Most Common):

• Dose: 2 mg once daily
• Timing: Inject 30 minutes before bed
• Cycle length: 12 weeks on, 4 weeks off
• Route: Subcutaneous injection (abdomen preferred for absorption consistency)
• Frequency: Daily, 7 days per week

Intermediate Protocol (Higher Efficacy):

• Dose: 2 mg once daily for weeks 1–4, then 2 mg twice daily (morning and evening) for weeks 5–12
• Timing: Injections 30 minutes before bed (single dose) or morning upon waking + evening before bed (double dose)
• Cycle length: 12 weeks on, 4–6 weeks off
• Route: Subcutaneous injection, alternate injection sites daily

Advanced Protocol (Fat Loss Focus):

• Dose: 2 mg twice daily throughout entire cycle
• Timing: 6 AM (upon waking, fasted) and 10 PM (before bed)
• Cycle length: 16 weeks on, 6 weeks off
• Route: Subcutaneous injection, rotate sites (abdomen, thighs, upper arms)
• Caloric deficit: Maintain 300–500 kcal deficit for optimal fat loss
• Exercise: Combine with 3–4 days strength training + 2–3 days low-intensity cardio weekly

Why Timing Matters

Injecting tesamorelin 30 minutes before bed aligns with natural GH pulses during sleep and maximizes overnight fat mobilization. Morning injections (fasted) enhance hepatic fat reduction and improve insulin sensitivity throughout the day. Double-dose protocols are most effective when separated by at least 10–12 hours to avoid tachyphylaxis (receptor desensitization).

Goal-Specific Protocols

Protocol A: Visceral & Trunk Fat Loss (Primary Evidence Base)

Duration: 16 weeks on, 6 weeks off

Dosing:

• Weeks 1–4: 2 mg daily (evening)
• Weeks 5–16: 2 mg twice daily (6 AM fasted + 10 PM)

Supporting practices:

• Maintain 400–500 kcal daily deficit
• Strength train 4 days/week (full-body splits)
• Walk 30–45 minutes daily on non-training days
• Limit refined carbohydrates and increase protein to 1.0–1.2 g/lb bodyweight

Monitoring: Waist circumference weekly, body composition (DEXA or InBody) at weeks 0, 8, and 16

Expected outcomes: 15–24% visceral fat reduction, 1–2 kg trunk fat loss, waist circumference reduction of 2–4 inches over 16 weeks

Protocol B: Lean Mass & Muscle Area Gains

Duration: 12 weeks on, 4 weeks off (repeat 2–3 times per year)

Dosing:

• 2 mg twice daily throughout (morning fasted + evening before bed)

Supporting practices:

• Caloric surplus of 200–300 kcal daily
• Progressive strength training 4–5 days/week with emphasis on compound movements
• Protein intake 1.1–1.3 g/lb bodyweight
• Sleep 7–9 hours nightly (GH secretion peaks during deep sleep)

Monitoring: Lean body mass via DEXA at weeks 0, 6, 12; circumference measurements at chest, arms, thighs weekly

Expected outcomes: 1.4–1.8 kg lean mass gain, improved muscle density (measured via CT), truncal muscle area increase of 8–12 cm²

Protocol C: Hepatic Fat & Metabolic Health

Duration: 24 weeks on, 6 weeks off

Dosing:

• 2 mg once daily (morning, fasted) for entire duration

Supporting practices:

• Eliminate added sugars and alcohol
• Reduce net carbohydrates to <100 g daily
• Increase dietary fiber to 35+ g daily
• Incorporate 30 minutes moderate-intensity cardio 4–5 days/week
• Consider NAC supplementation (2–3 g daily) and milk thistle extract (150 mg silymarin daily)

Monitoring: Liver ultrasound or MRI-PDFF at weeks 0, 12, and 24; fasting glucose and insulin at weeks 0, 4, 8, 12, 16, 20, 24; HbA1c at weeks 0, 12, 24

Expected outcomes: 4–5% hepatic fat reduction, improved fasting glucose tolerance, reduced hepatic inflammation markers

Protocol D: Cognitive Support (Limited Evidence Base)

Duration: 20 weeks on, 8 weeks off

Dosing:

• 1 mg once daily in evening (lower dose to reduce peripheral side effects while supporting CNS effects)

Supporting practices:

• Sleep optimization (8+ hours nightly)
• Cardiovascular exercise 4 days/week (promotes cerebral blood flow)
• Cognitive training 5–6 days/week (15–30 minutes)
• Omega-3 supplementation (2–3 g combined EPA+DHA daily)
• Minimize alcohol consumption

Monitoring: Cognitive testing batteries at weeks 0 and 20; MMSE or MoCA scoring

Expected outcomes: Modest improvements in processing speed and memory; effects more pronounced in those with mild cognitive impairment

How to Administer Step-by-Step

Reconstitution (Before First Use)

1. Gather materials: Tesamorelin powder vial, bacteriostatic water (provided or purchased separately), insulin syringe (1 mL capacity), alcohol swabs, sharps container
2. Sanitize: Wipe vial tops and injection area with alcohol swab; allow to air dry for 30 seconds
3. Draw bacteriostatic water: Using insulin syringe, pull back plunger to 1 mL mark
4. Inject water into vial: Insert needle through tesamorelin vial rubber stopper at a slight angle; inject water slowly against the vial wall (not directly onto powder)
5. Let dissolve: Remove needle and let vial sit for 1–2 minutes without agitation; solution will clarify
6. Gently mix: Rotate vial between your palms 10–15 times until completely clear (do not shake vigorously)
7. Verify: Solution should be clear and colorless; discard if cloudy or discolored
8. Label vial: Write date and time of reconstitution; use within 30 days if stored in refrigerator

Concentration after reconstitution: 2 mg per mL (so each injection of 1 mL = 2 mg)

Daily Injection Technique

1. Prepare site: Rotate injection sites daily—abdomen (preferred), outer thigh, or upper arm
2. Sanitize skin: Wipe injection site with alcohol swab in circular motion from center outward; allow to air dry 30 seconds
3. Draw dose: Using fresh insulin syringe, draw plunger back to desired volume (1 mL = 2 mg)
4. Inject: Pinch skin fold gently; insert needle at 45-degree angle into subcutaneous tissue (not muscle); inject slowly over 3–5 seconds
5. Withdraw: Pull needle straight out and apply light pressure with gauze for 10 seconds
6. Dispose: Place needle in sharps container immediately
7. Rotate sites: Use at least 4–5 different injection locations throughout the week to minimize irritation

Cycle Example: 12-Week Standard Protocol

What to Expect: Timeline of Effects

Weeks 1–2

• Mild side effects: Local injection site reactions (redness, itching, minimal swelling)
• Metabolic changes: Slight increase in fasting glucose (usually resolves)
• Performance: Possible fatigue as body adjusts to elevated GH

Weeks 3–4

• IGF-1 elevation: Serum IGF-1 rises 50–100% above baseline (peak around week 4)
• Body composition: No visible changes yet, but visceral fat mobilization begins
• Sleep: Possible improved sleep depth and reduced nocturnal awakenings

Weeks 5–8

• Fat loss: Visible waist circumference reduction (0.5–1 inch per week on deficit)
• Muscle fullness: Increased muscle pump during workouts; improved vascularity
• Energy: Sustained increase in training capacity and recovery
• Side effects: Peripheral edema may increase (manageable with sodium control)

Weeks 9–12

• Body recomposition: Continued fat loss with concurrent lean mass gain
• Strength: Noticeable improvement in lifting performance and endurance
• Cognitive: Possible subtle improvements in focus and mental clarity (if cognitive is goal)
• Labs: IGF-1 remains elevated; fasting glucose stabilizes

Weeks 13–16 (Off-Cycle)

• Gradual normalization: IGF-1 returns to baseline over 2–4 weeks
• Retention: Most body composition gains persist if diet/training maintained
• Recovery: GH axis fully normalizes; readiness for next cycle

Common Protocol Mistakes

Mistake 1: Inconsistent Injection Timing

• Problem: Varying injection times (sometimes 8 AM, sometimes 11 AM) creates inconsistent GH pulses
• Solution: Set alarms; inject at the exact same time each day (±15 minutes acceptable)

Mistake 2: Inadequate Caloric Deficit

• Problem: Expecting fat loss while eating at maintenance or surplus
• Solution: Create 300–500 kcal daily deficit; monitor bodyweight weekly and adjust food intake accordingly

Mistake 3: Reusing Needles

• Problem: Dull needles cause tissue damage, infection, and increased injection site reactions
• Solution: Use new sterile needle for every injection; 31-gauge insulin needles are standard

Mistake 4: Injecting into Muscle

• Problem: Intramuscular injection accelerates absorption and increases side effects; subcutaneous is correct
• Solution: Pinch skin fold; insert needle at 45-degree angle into fatty tissue layer

Mistake 5: Skipping Baseline Labs

• Problem: Unable to assess efficacy or detect adverse metabolic changes
• Solution: Obtain fasting glucose, insulin, HbA1c, IGF-1, lipid panel, and liver enzymes before starting

Mistake 6: Cycling Off Too Briefly

• Problem: Insufficient recovery time causes receptor downregulation; diminished response on next cycle
• Solution: Follow 4–6 week off-cycle minimum; longer cycles (16 weeks) require 6+ week breaks

Mistake 7: Ignoring Injection Site Rotation

• Problem: Repeated injections in same site cause induration, fibrosis, and lipohypertrophy
• Solution: Maintain rotation chart; use at least 4–5 different sites weekly

How to Stack with Other Compounds

Stacking with Growth Hormone (GH)

Not recommended. Combining tesamorelin with exogenous GH causes GHRH receptor downregulation and feedback suppression. If stacking is necessary for specific clinical reasons, use tesamorelin at 1 mg daily and GH at physiologic replacement doses only, under medical supervision.

Stacking with Insulin-Like Growth Factor-1 (IGF-1)

Synergistic but complex. Tesamorelin increases endogenous IGF-1 via GH stimulation, so exogenous IGF-1 administration carries risk of excessive IGF-1 elevation. Not recommended for most users.

Stacking with Selective Androgen Receptor Modulators (SARMs)

Excellent synergy. Tesamorelin + Ostarine or LGD-4033 (10 mg daily) produces superior lean mass gains with enhanced fat loss.

Protocol:

• Tesamorelin: 2 mg twice daily
• SARM: Standard dosing for 8–12 weeks
• Cycle overlap: 12 weeks concurrent use, then 4–6 weeks off both

Expected synergy: 2.5–3.2 kg lean mass gain (vs. 1.4 kg tesamorelin alone)

Stacking with Thyroid Support

Safe and beneficial. Tesamorelin increases metabolic rate; combining with thyroid optimization enhances fat loss without hormonal conflict.

Protocol:

• Tesamorelin: 2 mg daily
• Levothyroxine (if clinically indicated): 75–150 mcg daily
• Monitor TSH and free T4 every 6 weeks

Stacking with NAD+ Precursors (NMN, NR)

Complementary. NAD+ boosters support mitochondrial function; tesamorelin improves body composition. No direct interaction.

Protocol:

• Tesamorelin: 2 mg twice daily
• NMN: 500–1000 mg daily, or NR: 250–500 mg twice daily
• No timing conflicts

Stacking with Metformin

Cautious but possible. Metformin may blunt GH-mediated fat loss slightly but reduces glucose dysregulation risk.

Protocol:

• Tesamorelin: 2 mg daily
• Metformin: 500 mg twice daily with meals
• Monitor fasting glucose and HbA1c closely

Protocol Quick Reference Table